ORENCIA® (Non-English)

ORENCIA® is a selective immunosuppressive agent containing abatacept, a biologic fusion protein that modulates T-cell activation. It is used in the treatment of moderate to severe rheumatoid arthritis (RA) in adults and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 6 years and older. It is particularly effective in patients who have had an inadequate response to traditional disease-modifying antirheumatic drugs (DMARDs), including methotrexate or TNF-alpha inhibitors.

ORENCIA helps reduce joint inflammation, slow disease progression, and improve physical function. It is available as a 250 mg lyophilized powder for intravenous infusion and must be reconstituted and diluted before administration under medical supervision.

ORENCIA® is administered by intravenous infusion under healthcare supervision.

Key features:

• Dose based on body weight
  
• Infused over 30 minutes every 4 weeks after loading doses
  

Administration protocol:

• <60 kg: 500 mg (2 vials)
  
• 60–100 kg: 750 mg (3 vials)
  
• >100 kg: 1 g (4 vials)
  
• Initial doses at week 0, 2, and 4, followed by every 4 weeks
  
• Reconstituted in 10 mL sterile water per vial and diluted to 100 mL with 0.9% sodium chloride
  
• Use a 0.2–1.2 μm low-protein-binding filter during infusion

Indications:

• Moderate to severe rheumatoid arthritis (RA) in adults
  
• Active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged ≥6 years
  
• Used in combination with methotrexate
  

Contraindications:

• Hypersensitivity to abatacept or excipients
  
• Severe or uncontrolled infections
  
• Use with other biologic agents like TNF inhibitors, anakinra, or rituximab
  

Possible side effects:

• Common: Upper respiratory infections, headache, nausea
  
• Serious: Severe infections, malignancies, infusion reactions, hypersensitivity
  
• Pediatric: similar to adults, with fever and ear infections also observed
  

Each vial contains:

• 250 mg abatacept
  
• Excipients: maltoz, sodium dihydrogen phosphate monohydrate, sodium chloride
  

Each dose is reconstituted with 10 mL sterile water and diluted for IV infusion.

Each package contains:

• 1 glass vial with 250 mg lyophilized abatacept
  
• 1 latex-free disposable syringe
  
• Detailed instructions for preparation and administration
  

Yes, ORENCIA® may cause local and systemic side effects.

Very common (≥1/10):

• Upper respiratory infections
  

Common (≥1/100 to <1/10):

• UTIs, headache, dizziness
  
• Hypertension, nausea, rash
  
• Fatigue, abnormal liver function tests
  

Uncommon to rare:

• Tuberculosis, cancer, infusion reactions
  
• Allergic responses, herpes, COPD exacerbations
  

Storage conditions:

• Store between 2°C to 8°C (refrigerated)
  
• Keep in original packaging, protect from light
  
• Do not freeze
  
• Once reconstituted and diluted, use immediately, or refrigerate and use within 24 hours